1 / 12

Tigecycline Products Market

Read here the market research report published by CMI team

PriyaCmi
Download Presentation

Tigecycline Products Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. TIGECYCLINE PRODUCTS MARKET ANALYSIS TigecyclineProducts Market, by Application (Urinary Tract Infections, Skin and Soft Tissue Infections, Complicated Intra-Abdominal Infections, Community-Acquired Bacterial Pneumonia, Gonorrhea, and Chlamydia), by Distribution Channel (Online Retail Pharmacies And Offline Retail Pharmacies), and by Region (North America, Latin America, Europe, Middle East, Asia Pacific, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

  3. Market: Drivers • The increasing prevalence of gonorrhea in the U.S. is driving demand for tigecycline products in the market. For instance, according to the Centers for Disease Control and Prevention’s 2017 report, in the U.S, around 555,608 cases of gonorrhea were reported. Therefore, pharmaceutical companies are focusing on launching products for treatment of bacterial infections due to increasing prevalence. For instance, in 2017, Sandoz Inc. launched AP-rated generic version of Tygacil (Tigecycline) injection at a cheaper price compared to branded products in order to increase affordability of the drug. These factors are expected to drive growth of global tigecycline products market.

  4. COVID-19 Impact AnalysisThe COVID-19 pandemic has affected several markets across the globe. Pharmaceutical companies are facing difficulties such as regulatory revisions, changes in demand, delay in generic medicine approvals, disruption in supply chain, and product exportation restriction due to lockdown policies implemented by governments. These factors are negatively affecting the growth of the global tigecycline products market.

  5. Market Restraints • Tigecycline antibiotic is characterized by side effects such as lower back or side pain, painful or difficult urination, problems with vision or hearing, cough or hoarseness, fever or chills, and headache. • Moreover,the use of  tigecycline is restricted due to increase in mortality in hospital-acquired or ventilator-associated pneumonia. Moreover, patients prefer oral tablets (amoxicillin) to injection (tigecycline) for treatment of bacterial infection, due to the cost effectiveness of oral amoxicillin. Cost of 500 mg amoxicillin oral tablet is US$ 23.99, while cost of the tigecycline injection is US$ 79.22. These factors are expected to restrain growth of the global tigecycline products market.

  6. Regional Analysis • On the basis of region, the global tigecycline products market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In North America, the demand for use of tigecycline is increasing due to high prevalence of chlamydia trachomtis. • For instance, according to the Centers for Disease Control and Prevention, in 2016, 1,598,354 cases of chlamydia trachomatis infection were reported in the U.S., and 497.3 cases per 100,000 were reported in 2015.

  7. Market Trends • Therefore, pharmaceutical companies are focusing on launching product for treatment of bacterial infectious diseases. For instance, in February 2020, European Medicines Agency approved marketing authorization of tigecycline injection by Accord Healthcare for treatment of bacterial skin diseases. These factors are expected to drive growth of the global tigecycline products market during the forecast period. •   Therefore, pharmaceutical companies are focusing on product launches for the treatment of bacterial infectious disease. For instance, in 2016, Fresenius Kabi announced the launch of Tigecycline injection, a generic version of Pfizer’s tygacil with single dose vial in the U.S.

  8. Competitive Section • Key players operating in the global tigecycline products market are Amneal Pharmaceuticals, Inc., Novartis International AG, Xellia pharmaceuticals ApS, Accord Healthcare Inc., Apotex, Inc., AurobindoPharma Limited, Fresenius Kabi USA LLC, Pfizer Inc., Abbott Laboratories, and AstraZeneca plc. • Market Taxonomy: • On the basis of application, the global tigecycline products market is segmented into: • Urinary Tract Infections (UTI) • Skin and Soft Tissue Infections • Complicated Intra-Abdominal Infections • Community-acquired Bacterial Pneumonia • Gonorrhea • Chlamydia • Others

  9. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Buy Now Reference https://www.coherentmarketinsights.com/ongoing-insight/tigecycline-products-market-4168

  10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  11. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  12. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related